Table 1 Baseline characteristics.
From: The gut microbiota during tamoxifen therapy in patients with breast cancer
Baseline characteristics | |||
|---|---|---|---|
Age—Years | History of smoking (past and present) – N (%) | ||
Mean (SD) | 66 (8) | Yes | 44 (73.3) |
Range | 50–86 | No | 17 (27.4) |
Unknown | 1 (1.6) | ||
BMI—kg/m2 | Total years of smoking | ||
Mean (SD) | 26 (4) | Median (IQR) | 10 (25) |
Range | 18.7–35.4 | ||
Tumor type—N (%) | Prior systemic therapy for breast cancer | ||
Invasive carcinoma of no special type (NST) | 42 (67.7) | Yes | 14 (22.6) |
Lobular | 16 (25.8) | No | 48 (77.4) |
Mucinous | 4 (6.5) | ||
Clinical tumor stage—N (%) | Days between the last systemic therapy and T0 fecal sample | ||
Stage 0 | 1 (1.6) | Median (IQR) | 47.5 (18.3) |
Stage 1 | 34 (54.8) | Range | 32–156 |
Stage 2 | 26 (42) | ||
Stage 3 | 1 (1.6) | ||
Pathologic tumor stage—N (%) | Prior prophylactic antibiotic use during surgery | ||
Stage 0 | 3 (4.8) | Yes | 30 (48.4) |
Stage 1 | 34 (54.8) | No | 32 (51.6) |
Stage 2 | 25 (40.3) | ||
Tumor focality—N (%) | Type of breast surgery – N (%) | ||
Unifocal | 51 (82.3) | Mastectomy | 24 (38.7) |
Multifocal | 11 (17.7) | Breast-conserving surgery | 38 (61.2) |
Karnofsky Performance Score—N (%) | Direct breast reconstruction – N (%) | ||
50–60 | 4 (6.5) | Yes | 23 (37) |
70–80 | 18 (29) | No | 39 (63) |
90–100 | 38 (61.3) | ||
Unknown | 2 (3.2) | ||
Antibiotic use last year—N (%) | Days between breast surgery and T0 fecal sample | ||
Yes | 39 (63) | Median (IQR) | 26 (18) |
No | 23 (37) | Range | 10–338 |
Probiotic use last year—N (%) | Radiotherapy – N (%) | ||
Yes | 4 (6.5) | Yes | 45 (72.6) |
No | 46 (74.2) | No | 17 (27.4) |
Unknown | 12 (19.4) | ||
ER status—% | Timing start tamoxifen therapy – N (%) | ||
Median (IQR) | 100 (0) | Before radiotherapy | 12 (26.6) |
During radiotherapy | 30 (66.7) | ||
After radiotherapy | 3 (6.7) | ||
PR status—% | Days between start tamoxifen and z-endoxifen detection | ||
Median (IQR) | 80 (85) | Median (IQR) | 58 (29) |
